Spyre Therapeutics saw a significant boost in its stock price after Deutsche Bank initiated coverage with a price target of $43. This positive outlook from a major financial institution highlights the company's potential for growth and investor interest, making it a noteworthy development in the biotech sector.

Deutsche Bank has started coverage on Spyre stock with a positive Buy rating, indicating strong confidence in the company's future performance. This move is significant as it highlights the bank's belief in Spyre's potential for growth, which could attract more investors and boost the stock's value. Such endorsements from major financial institutions often lead to increased market interest and can positively influence the company's trajectory.